Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Daiichi Sankyo Ltd (OP: DSKYF )

28.77 -1.53 (-5.05%)
Streaming Delayed Price Updated: 3:42 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,543
Open 31.09
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 30.30
Today's Range 28.61 - 31.09
52wk Range 25.72 - 44.64
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... 
Via Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to... 
Via Benzinga

Performance

YTD
+9.31%
+9.31%
1 Month
-12.23%
-12.23%
3 Month
-26.61%
-26.61%
6 Month
-17.86%
-17.86%
1 Year
+8.77%
+8.77%

More News

Read More
Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront
Via Talk Markets
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
Via Benzinga
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
Via Benzinga
Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
Via Benzinga
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Via Benzinga
Exposures Product Safety
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Via Benzinga
Exposures Product Safety
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Via Benzinga
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Via Benzinga
Double Good News For AstraZeneca's Breast Cancer Drugs
Via Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
Via Benzinga
Exposures Product Safety
What's Going On With Pfizer Stock Today?
Via Benzinga
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
Via Benzinga
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
Via Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Via Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
Via Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
Via Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Via Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Via Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
Via Benzinga
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
Via Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
Via Benzinga
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.